Assertio (ASRT)
(Delayed Data from NSDQ)
$1.16 USD
+0.03 (2.65%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $1.16 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.16 USD
+0.03 (2.65%)
Updated Oct 17, 2024 04:00 PM ET
After-Market: $1.16 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value C Growth B Momentum C VGM
Zacks News
Oncternal Therapeutics (ONCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Oncternal Therapeutics (ONCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Earnings Season Could Be Great for Assertio (ASRT)
by Zacks Equity Research
Assertio (ASRT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Assertio (ASRT) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Assertio (ASRT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Assertio (ASRT) Soars 5.1%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Assertio (ASRT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.
Cronos Group (CRON) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
Cronos (CRON) delivered earnings and revenue surprises of -180% and 7.20%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
FibroGen (FGEN) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
FibroGen (FGEN) delivered earnings and revenue surprises of 26.32% and 43.89%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Assertio (ASRT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed at $5.12 in the latest trading session, marking a +1.19% move from the prior day.
Catalyst (CPRX) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Revenues of Catalyst Pharmaceuticals (CPRX) are expected to have been driven by the sales of its only marketed product, Firdapse, for treating LEMS, along with the drug's label expansion for the treatment of pediatric patients.
Assertio Holdings, Inc. (ASRT) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Assertio (ASRT) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Assertio (ASRT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $5.10, moving +0.59% from the previous trading session.
Ardelyx Inc. (ARDX) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Ardelyx (ARDX) is expected to report better-than-expected sales growth of its only marketed product, Ibsrela (tenapanor) and provide an update on the NDA resubmission timeline for Xphozah, tenapanor.
Assertio (ASRT) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
On Assertio Holdings' (ASRT) Q4 earnings call, investors will focus on the sales performance of its marketed products.
Why Assertio (ASRT) Could Beat Earnings Estimates Again
by Zacks Equity Research
Assertio (ASRT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
How to Find Strong Medical Stocks Slated for Positive Earnings Surprises
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Zoetis (ZTS) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Higher sales of Zoetis' (ZTS) key drugs like Apoquel, Cytopoint, Simparica Trio, Librela and Solensia are expected to have driven sales, partially offset by lower sales of livestock, cattle, poultry and swine products.
Investors Heavily Search Assertio Holdings, Inc. (ASRT): Here is What You Need to Know
by Zacks Equity Research
Assertio (ASRT) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Assertio (ASRT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $4.18, moving +1.95% from the previous trading session.
Assertio (ASRT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Assertio (ASRT) closed at $4.02, marking a +0.25% move from the previous day.
Assertio (ASRT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed at $4.06 in the latest trading session, marking a +1.25% move from the prior day.
Zacks Industry Outlook Highlights Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics
by Zacks Equity Research
Dyne Therapeutics, Silence Therapeutics, Alaunos Therapeutics, Assertio Holdings and Acer Therapeutics are part of the Zacks Industry Outlook article.
5 Stocks to Buy as the Drug Industry Bets Big on Innovation
by Kinjel Shah
Innovation is expected to continue driving growth in the Medical-Drugs industry in 2023. DYN, SLN, TCRT, ASRT and ACER may prove to be good additions to one's portfolio.
Corcept (CORT) Rides on Robust Korlym Sales, High Reliance a Woe
by Zacks Equity Research
Corcept's (CORT) Cushing's syndrome drug Korlym is witnessing higher sales and a strong uptake since approval. However, sole dependence on Korlym for revenues remains a headwind.
Assertio (ASRT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Assertio (ASRT) closed the most recent trading day at $4.22, moving +1.44% from the previous trading session.
Take the Zacks Approach to Beat the Market: Boeing, Halliburton, Starbucks in Focus
by Abhinab Dasgupta
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.